Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 394

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Open access
van den Bent, Martin J, Baumert, Brigitta, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Baurain, Jean Francais, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Brachman, David G, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Weber, Damien C, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Pascoe, Sarah, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, van Heuvel, Irene, Stupp, Roger, Aldape, Ken, Jenkins, Robert B, Dubbink, Hendrikus Jan, Dinjens, Winand N M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, Wick, Wolfgang, Kros, Johan M·2017·The Lancet

Abstract

Summary Background The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas. Methods This was a phase 3, randomised, open-label study with a 2 × 2 factorial design. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with WHO performance status scores of 0–2. The randomisation schedule was generated with the electronic EORTC web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the minimisation technique, to receive radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy) alone or with adjuvant temozolomide (12 4-week cycles of 150–200 mg/m2 temozolomide given on days 1–5); or to receive radiotherapy with concurrent temozolomide 75 mg/m2 per day, with or without adjuvant temozolomide. The primary endpoint was overall survival adjusted for performance status score, age, 1p loss of heterozygosity, presence of oligodendroglial elements, and MGMT promoter methylation status, analysed by intention to treat. We did a planned interim analysis after 219 (41%) deaths had occurred to test the null hypothesis of no efficacy (threshold for rejection p<0·0084). This trial is registered with ClinicalTrials.gov, number NCT00626990. Findings At the time of the interim analysis, 745 (99%) of the planned 748 patients had been enrolled. The hazard ratio for overall survival with use of adjuvant temozolomide was 0·65 (99·145% CI 0·45–0·93). Overall survival at 5 years was 55·9% (95% CI 47·2–63·8) with and 44·1% (36·3–51·6) without adjuvant temozolomide. Grade 3–4 adverse events were seen in 8–12% of 549 patients assigned temozolomide, and were mainly haematological and reversible. Interpretation Adjuvant temozolomide chemotherapy was associated with a significant survival benefit in patients with newly diagnosed non-co-deleted anaplastic glioma. Further analysis of the role of concurrent temozolomide treatment and molecular factors is needed. Funding Schering Plough and MSD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)31442-3

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 394

Metadata

Authors
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., Wheeler, H., Chinot, O. L., Gill, S., Griffin, M., Brachman, D. G., Taal, W., Rudà, R., Weller, M., McBain, C., Reijneveld, J., Enting, R. H., Weber, D. C., Lesimple, T., Clenton, S., Gijtenbeek, A., Pascoe, S., Herrlinger, U., Hau, P., Dhermain, F., van Heuvel, I., Stupp, R., Aldape, K., Jenkins, R. B., Dubbink, H. J., Dinjens, W. N. M., Wesseling, P., Nuyens, S., Golfinopoulos, V., Gorlia, T., Wick, W., & Kros, J. M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-10
Volume
390
Issue
10103
Pages
1645-1653
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2744160381
Cited by
394
References
7
FWCI
25.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. https://app.cochat.ai/papers/10.1016/s0140-6736(17)31442-3
The paper
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., Wheeler, H., Chinot, O. L., Gill, S., Griffin, M., Brachman, D. G., Taal, W., Rudà, R., Weller, M., McBain, C., . . . Kros, J. M. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet. https://doi.org/10.1016/s0140-6736(17)31442-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.